Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.

Choudry HA, Pai RK, Shuai Y, Ramalingam L, Jones HL, Pingpank JF, Ahrendt SS, Holtzman MP, Zureikat AH, Zeh HJ, Bartlett DL.

Ann Surg Oncol. 2018 Jan;25(1):76-82. doi: 10.1245/s10434-017-6214-7. Epub 2017 Nov 6.

PMID:
29110275
2.

Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Horvath P, Yurttas C, Birk P, Struller F, Königsrainer A.

Langenbecks Arch Surg. 2018 Dec;403(8):985-990. doi: 10.1007/s00423-018-1735-5. Epub 2018 Dec 1.

PMID:
30506401
3.

Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M.

Ann Surg Oncol. 2018 Feb;25(2):404-413. doi: 10.1245/s10434-017-6252-1. Epub 2017 Nov 20.

PMID:
29159742
4.

Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.

Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B.

Ann Surg Oncol. 2016 Dec;23(13):4316-4321. Epub 2016 Jul 5.

PMID:
27380645
5.

Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M.

Ann Surg Oncol. 2007 Aug;14(8):2300-8. Epub 2007 May 18.

PMID:
17510772
6.

Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.

Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M.

Ann Surg Oncol. 2016 Dec;23(13):4222-4230. Epub 2016 Jun 28.

PMID:
27352203
7.

Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.

Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.

Eur J Surg Oncol. 2015 Mar;41(3):396-9. doi: 10.1016/j.ejso.2014.08.476. Epub 2014 Sep 2.

PMID:
25216980
8.

Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.

Bhatt A, Mishra S, Prabhu R, Ramaswamy V, George A, Bhandare S, Shah M, Mehta S.

Eur J Surg Oncol. 2018 Jul;44(7):1105-1111. doi: 10.1016/j.ejso.2018.03.032. Epub 2018 Apr 12.

PMID:
29685759
9.

Curative Surgical Resection as a Component of Multimodality Therapy for Peritoneal Metastases from Goblet Cell Carcinoids.

Radomski M, Pai RK, Shuai Y, Ramalingam L, Jones H, Holtzman MP, Ahrendt SA, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA.

Ann Surg Oncol. 2016 Dec;23(13):4338-4343. Epub 2016 Jul 11.

PMID:
27401448
10.

Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.

Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B.

Colorectal Dis. 2015 Aug;17(8):698-703. doi: 10.1111/codi.12924.

PMID:
25704482
11.

Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.

Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.

Eur J Surg Oncol. 2014 May;40(5):515-520. doi: 10.1016/j.ejso.2013.12.021. Epub 2014 Jan 12.

PMID:
24462284
12.

The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Kusamura S, Baratti D, Hutanu I, Gavazzi C, Morelli D, Iusco DR, Grassi A, Bonomi S, Virzì S, Haeusler E, Deraco M.

Eur J Surg Oncol. 2015 Aug;41(8):1097-105. doi: 10.1016/j.ejso.2015.04.005. Epub 2015 May 16.

PMID:
26026742
13.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.

Delhorme JB, Severac F, Averous G, Glehen O, Passot G, Bakrin N, Marchal F, Pocard M, Lo Dico R, Eveno C, Carrere S, Sgarbura O, Quenet F, Ferron G, Goéré D, Brigand C; French National Network of Peritoneal Surface Malignancies (RENAPE).

Br J Surg. 2018 May;105(6):668-676. doi: 10.1002/bjs.10716. Epub 2018 Feb 7.

PMID:
29412465
14.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

López-López V, Cascales-Campos PA, Gil E, Arevalo J, Gonzalez A, Gil J, Muñoz-Casares FC, Melero JT, Barrios P, Morales R, Ramos I, Ortega G, Camps B, González-Bayón L, Bretcha-Boix P, Farré-Alegre J, González-Moreno S, Parrilla P.

Clin Transl Oncol. 2017 Nov;19(11):1388-1392. doi: 10.1007/s12094-017-1728-9. Epub 2017 Aug 10.

PMID:
28812240
15.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.

Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, Sarpel U, Labow DM.

J Gastrointest Surg. 2014 May;18(5):1024-31. doi: 10.1007/s11605-014-2477-5. Epub 2014 Feb 28.

PMID:
24577736
16.

Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.

Bhatt A, Sheshadri D, Chandan G, Ramaswamy V, Pandey J, Bhorkar N, Agrawal D, Mehta S.

J BUON. 2017 Jan-Feb;22(1):251-257.

17.

Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM.

Ann Surg Oncol. 2015 May;22(5):1716-21. doi: 10.1245/s10434-014-3985-y. Epub 2014 Aug 22.

PMID:
25145504
18.

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.

Liu Y, Ishibashi H, Hirano M, Takeshita K, Mizumoto A, Ichinose M, Nishino E, Kashu I, Yamamoto Y, Sugarbaker PH, Yonemura Y.

Ann Surg Oncol. 2015 Aug;22(8):2799-805. doi: 10.1245/s10434-014-4336-8. Epub 2015 Jan 9.

PMID:
25572681
19.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Azzam AZ, Alyahya ZA, Wusaibie AAA, Amin TM.

Indian J Gastroenterol. 2017 Nov;36(6):452-458. doi: 10.1007/s12664-017-0799-4. Epub 2017 Nov 29.

PMID:
29185227
20.

Supplemental Content

Support Center